^
Association details:
| Biomarker: | FGF19 expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR 11/ICON-7
Published date:
12/27/2023
Excerpt:
In this exploratory analysis of tissue samples from the pivotal, prospective, randomized phase III AGO-OVAR 11/ICON-7 trial (NCT00483782), we investigate the prognostic and predictive potential of FGFR/FGF expression (FGFR1, FGFR2, FGFR3, and FGFR4 or their ligands, FGF1 and FGF19)....Expression of FGFR1, FGFR2, FGF1, and FGF19 was associated with progression-free survival (PFS) in both uni- and multivariate (FGFR1: HR=1.6, p<0.001; FGFR2: HR=1.6, p=0.002; FGF1: HR=2.3, p<0.001; FGF19: HR=0.7; p=0.007) analysis.
DOI:
https://doi.org/10.1016/j.labinv.2023.100321
Trial ID:
